Drug – bio-affecting and body treating compositions – Plant material or plant extract of undetermined constitution... – Containing or obtained from compositeae
Reexamination Certificate
2000-06-02
2002-06-25
Prats, Francisco (Department: 1651)
Drug, bio-affecting and body treating compositions
Plant material or plant extract of undetermined constitution...
Containing or obtained from compositeae
C424S725000
Reexamination Certificate
active
06410062
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to the topical treatment and prevention of inflammatory disorders and related conditions using extracts of feverfew (
Tanacetum parthenium
).
BACKGROUND OF THE INVENTION
Tanacetum parthenium,
a plant commonly known as Feverfew, has been recognized since the Middle Ages as having significant medicinal properties when taken orally—used as a general febrifuge, hence its common name. Many have isolated extracts of the plant and those extracts have been used to orally treat migraines, arthritis, and bronchial complaints. (See Johnson et al, U.S. Pat. No. 4,758,433, discussing the treatment of a variety of diseases by oral, inhalation, injection or suppository administration of the extract and see WO 94 06800, discussing a extract of feverfew which contains parthenolide).
Extracts of feverfew contain many components. Although not all components have been isolated and characterized, the known components of an extract of feverfew contain a significant number of biologically active components. To date, the chemical constituents of whole feverfew extract are as follows: apigenin-7-glucoside, apigenin-7-glucuronide, 1-&bgr;-hydroxyarbusculin, 6-hydroxykaempferol-3,7-4′-trimethylether (Tanetin), 6-hydroxykaempferol-3,7-dimethyl ether, 8-&bgr;-reynosin, 10-epicanin, ascorbic acid, beta-carotene, calcium, chromium, chrysanthemolide, chrysanthemomin, chrysarten-A, chrsyarten-c, chrysoeriol-7-glucuronide, cobalt, cosmosiin, epoxyartemorin, luteolin-7-glucoside, luteolin-7-glucuronide, mangnoliolide, parthenolide, quercetagentin-3,7,3′-trimethylether, quercetagetin-3′7-dimethylether, reynosin, tanaparthin, tanaparthin-1&agr;,4&agr;-epoxide, tanaparthin-1&bgr;,4&bgr;-epoxide, &bgr;-costunolide, 3-&bgr;-hydroxy-parthenolide, and 3,7,3′-trimethoxyquercetagetin. The specific role that each of these component compounds plays in the biological activity of feverfew is to date unknown. However, some information is known about the allergic reactions to the extract. It is believed that many of these allergic reactions are caused by the &agr;-unsaturated &ggr;-lactones such as parthenolide. (See, Arch. Dermatol. Forsch. 1975, 251 (3):235-44; Arch. Dermatol. Forsch 1976, 255 (2):111-21; Contact Dermatitis, 1988, 38 (4):207-8; Am. J. Contact Dermatol. 1998-9 (1):49-50; Br. J. Dermatol, 1995, 132 (4): 543-47).
Despite the existence of oral methods of using extracts of feverfew, there are no defined methods for topically using these extracts to treat or prevent inflammatory disorders and related conditions. In addition, there are no teachings which describe the use of an extract of feverfew which does not contain the allergy causing &agr;-unsaturated &ggr;-lactones. These are two areas which are addressed by this invention.
SUMMARY OF THE INVENTION
This invention relates to a method of treating or preventing inflammatory disorders and related conditions using an extract of feverfew. More particularly, the invention includes a method of treating or preventing inflammatory disorders and related conditions by applying a topical composition containing an effective amount of an extract of feverfew to a patient. The method of this invention includes a method of treating or preventing inflammatory disorders and related conditions of the skin by applying a topical composition comprising an effective amount of an extract of feverfew to a patient. Still further, the invention includes a method of treating and preventing inflammatory disorders and related conditions by applying a topical composition containing an effective amount of an extract of feverfew to a patient where said extract is substantially free of &agr;-unsaturated &ggr;-lactone. Further, the invention includes a method of treating and preventing inflammatory disorders and related conditions of the skin by applying a topical composition containing an effective amount of an extract of feverfew to a patient where said extract is substantially free of &agr;-unsaturated &ggr;-lactone.
REFERENCES:
patent: 4758433 (1988-07-01), Johnson et al.
patent: 6103218 (2000-08-01), Brucker et al.
patent: 6153208 (2000-11-01), McAtee et al.
patent: WO9406800 (1994-03-01), None
Barasby et al. Planta Medica (1993), vol. 59, No. 1, pp. 20-25.*
Derwent English abstract of HU 210294 B (1995).*
Lamminpaa et al. Contact Dermatitis (1996), vol. 34, No. 5, pp. 330-335.*
U.S. application No. 09/385,513, Indena, filed Aug. 29, 1999.
Arch. Dermatol. Forsch 1975, 251(3):235-44.
Arch. Dermatol. Res. 1976, 255(2):111-21.
Contact Dermatitis 1988, 38(4):207-8.
Am. J. Contact Dermatol. 1998-9(1):49-50.
Br. J. Dermatol, 1995, 132(4):543-47.
XP-002147441 Biosis:Biosciences Information Service, Barasby R.W.J. et al.: Philadelphia, PA 1993.
Callaghan Theresa
Gendimenico Gerard
Martin Katharine
Oddos Thierry
Coe Susan D.
Johnson & Johnson Consumer France SAS I3540
Prats Francisco
LandOfFree
Method for the topical treatment and prevention of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for the topical treatment and prevention of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for the topical treatment and prevention of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2904411